XML 95 R81.htm IDEA: XBRL DOCUMENT v3.23.1
Note 14 - Segment Data - Operating Segment Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2021
Revenues $ 219,080 $ 184,335 $ 133,937
Gross profit (loss) 133,693 109,090 87,014
Operating expenses 130,373 104,388 74,656
Operating income 3,320 4,702 12,358
Nonoperating expense (3,709) (1,128) (10,055)
Total (loss) earnings before income taxes (389) 3,574 2,303
Operating Segments [Member]      
Revenues 219,080 184,335 133,937
Gross profit (loss) 133,733 109,255 87,017
Operating expenses 130,373 104,388 74,656
Operating income 3,320 4,702 12,358
Nonoperating expense 3,709 1,128 10,055
Operating Segments [Member] | Clinical Genomics [Member]      
Revenues [1] 62,299 32,840 0
Gross profit (loss) 32,485 11,941 0
Operating Segments [Member] | Sterilization and Disinfection Control [Member]      
Revenues [1] 64,609 59,044 53,119
Gross profit (loss) 46,520 43,720 39,870
Operating Segments [Member] | Biopharmaceutical Development [Member]      
Revenues [1] 47,365 45,579 33,892
Gross profit (loss) 30,340 28,605 21,035
Operating Segments [Member] | Calibration Solutions [Member]      
Revenues [1],[2] 44,807 46,872 46,926
Gross profit (loss) 24,388 24,989 26,112
Corporate, Non-Segment [Member]      
Revenues [1],[3] 0 0 0
Gross profit (loss) [3] $ (40) $ (165) $ (3)
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.
[3] Unallocated corporate expenses and other business activities are reported within Corporate and Other.